Bluevac BTV (previously known as Bluevac BTV8)

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated]

Available from:

CZ Veterinaria S.A.

ATC code:

QI04AA02

INN (International Name):

bluetongue virus inactivated, serotype 8

Therapeutic group:

Sheep; Cattle

Therapeutic area:

Immunoloġiċi

Therapeutic indications:

SheepActive-tilqim kontra l-virus tal-bluetongue tas-serotip 8 għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi. Il-bidu tal-immunità: 20 jum wara t-tieni doża. Tul ta 'żmien tal-immunità: sena wara t-tieni doża. CattleActive-tilqim kontra l-virus tal-bluetongue tas-serotip 8 għall-prevenzjoni kontra viremja. Il-bidu tal-immunità: 31 jum wara t-tieni doża. Tul ta 'żmien tal-immunità: sena wara t-tieni doża.

Product summary:

Revision: 7

Authorization status:

Awtorizzat

Authorization date:

2011-04-14

Patient Information leaflet

                                18/24
B. FULJETT TA’ TAGĦRIF FIL-PAKKETT
19/24
FULJETT TA’ TAGĦRIF GĦAL
BLUEVAC BTV SUSPENSJONI GĦAL INJEZZJONI GĦAL FRAT U NAGĦAĠ
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID
FIS-SUQ, U L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI TAL-
MANIFATTURA RESPONSABBLI MILL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq u l-manifattur
responsabbli għall-ħrug tal-lott:
_ _
CZ Veterinaria, S.A.
La Relva s/n - Torneiros
36410 Porriño (Spanja)
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
BLUEVAC BTV Suspensjoni għal injezzjoni għal frat u nagħaġ
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull ml tal-vaċċin fih:
SUSTANZI ATTIVI:
Virus inattivat tal-Bluetongue (BTV)
Wieħed mis-serotipi differenti tal-virus inattivat tal-bluetongue li
ġejjin -
Virus inattivat tal-bluetongue, serotip 1 (BTV-1), razza
BTV-1/ALG/2006/01
≥ 22.60 µg/ml
Virus inattivat tal-bluetongue, serotip 4 (BTV-4), razza
BTV-4/SPA-1/2004
≥ 2.55 µg/ml
Virus inattivat tal-bluetongue, serotip 8 (BTV-8), razza
BTV8/BEL/2006/01
≥ 55.80 µg/ml
SUSTANZI MHUX ATTIVI:
Aluminium hydroxide
6 mg
Purified saponin (Quil A)
0.05 mg
EĊĊIPJENTI:
Thiomersal
0.1 mg
It-tip tar-razza inkluż fil-prodott finali se jintgħażel abbażi
tas-sitwazzjoni epidemijoloġika fil-ħin tal-
manifattura u sejjer jiġi ddikjarat fuq it-tikketta.
Suspensjoni bajda jew bajda rożana.
_ _
_ _
4.
INDIKAZZJONI
Ngħaġ
Għat-tilqim attiv tan-nagħaġ biex tkun impeduta viremija* kkawżata
mis-serotip 1 jew 4 jew 8 tal-virus
tal-bluetongue u biex jitnaqqsu s-sinjali kliniċi kkawżati minn
virus tal-bluetongue serotip 8.
20/24
* Taħt il-livell ta’ kxif mill-metodu tal-RT-PCR validat f’1
log10 TCID
50
/ml għal serotipi 8 u 4, u 1.3
log10
TCID
50
/ml għal serotip 1.
Bidu tal-immunità:
21 jum wara t-tmiem tal-iskema tat-tilqima primarja.
Tul ta’ żmien tal-immunità:
sena wara t-tmiem tal-iskema tat-tilqima primarja.
Frat
Għat-tilqim attiv ta’ frat minn età biex tkun i
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/24
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2/24
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
BLUEVAC BTV Suspensjoni għal injezzjoni għal frat u ngħaġ
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull ml tal-vaċċin fih:
SUSTANZI ATTIVI:
Virus inattivat tal-Bluetongue (BTV)
Wieħed mis-serotipi tal-virus inattivat tal-bluetongue li ġejjin:
Virus inattivat tal-bluetongue, serotip 1 (BTV-1), razza
BTV-1/ALG/2006/01
≥ 22.60 µg/ml
Virus inattivat tal-bluetongue, serotip 4 (BTV-4), razza
BTV-4/SPA-1/2004
≥ 2.55 µg/ml
Virus inattivat tal-bluetongue, serotip 8 (BTV-8), razza
BTV8/BEL/2006/01
≥ 55.80 µg/ml
SUSTANZI MHUX ATTIVI:
Aluminium hydroxide
6 mg
Purified saponin (Quil A)
0.05 mg
EĊĊIPJENTI:
Thiomersal
0.1 mg
Għal-lista sħiħa ta’ eċċipjenti, ara s-sezzjoni 6.1.
It-tip tar-razza inkluż fil-prodott finali se jintgħażel abbażi
tas-sitwazzjoni epidemijoloġika fil-ħin tal-
manifattura u sejjer jiġi ddikjarat fuq it-tikketta.
3.
GĦAMLA FARMAĊEWTIKA
Suspensjoni għall-injezzjoni
Suspensjoni bajda jew bajda rożana.
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Ngħaġ u frat.
4.2
INDIKAZZJONIJIET GĦALL-UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT
Ngħaġ
Għat-tilqim attiv tan-ngħaġ biex tkun impeduta viremija* kkawżata
mis-serotip 1 jew 4 jew 8tal-virus tal-
bluetongue u biex jitnaqqsu s-sinjali kliniċi kkawżati minn virus
tal-bluetongue serotip 8.
*
Taħt il-livell ta’ kxif mill-metodu tal-RT-PCR validat f’1 log10
TCID50/ml għal serotipi 8 u 4, u 1.3
log10 TCID50/ml għal serotip 1.
Bidu tal-immunità:
21 jum wara t-tmiem tal-iskema tat-tilqima primarja.
Tul ta’ żmien tal-immunità:
sena wara t-tmiem tal-iskema tat-tilqima primrja.
3/24
Frat
Għat-tilqim attiv ta’ frat minn età biex tkun impeduta viremija*
kkawżata minn virus tal-bluetongue
serotip 1 jew 4 jew 8.
* Taħt il-livell ta’ kxif mill-metodu tal-RT-PCR validat f’1
log10 TCID
50
/ml għal serotipi 8 u 4, u 1.3
log10
TCID
50
/ml għal serotip 1.
Bidu
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-10-2020
Public Assessment Report Public Assessment Report Bulgarian 27-10-2020
Patient Information leaflet Patient Information leaflet Spanish 27-10-2020
Public Assessment Report Public Assessment Report Spanish 27-10-2020
Patient Information leaflet Patient Information leaflet Czech 27-10-2020
Public Assessment Report Public Assessment Report Czech 27-10-2020
Patient Information leaflet Patient Information leaflet Danish 27-10-2020
Public Assessment Report Public Assessment Report Danish 27-10-2020
Patient Information leaflet Patient Information leaflet German 27-10-2020
Public Assessment Report Public Assessment Report German 27-10-2020
Patient Information leaflet Patient Information leaflet Estonian 27-10-2020
Public Assessment Report Public Assessment Report Estonian 27-10-2020
Patient Information leaflet Patient Information leaflet Greek 27-10-2020
Public Assessment Report Public Assessment Report Greek 27-10-2020
Patient Information leaflet Patient Information leaflet English 27-10-2020
Public Assessment Report Public Assessment Report English 12-01-2018
Patient Information leaflet Patient Information leaflet French 27-10-2020
Public Assessment Report Public Assessment Report French 27-10-2020
Patient Information leaflet Patient Information leaflet Italian 27-10-2020
Public Assessment Report Public Assessment Report Italian 27-10-2020
Patient Information leaflet Patient Information leaflet Latvian 27-10-2020
Public Assessment Report Public Assessment Report Latvian 27-10-2020
Patient Information leaflet Patient Information leaflet Lithuanian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-10-2020
Public Assessment Report Public Assessment Report Lithuanian 27-10-2020
Patient Information leaflet Patient Information leaflet Hungarian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 27-10-2020
Public Assessment Report Public Assessment Report Hungarian 27-10-2020
Patient Information leaflet Patient Information leaflet Dutch 27-10-2020
Public Assessment Report Public Assessment Report Dutch 27-10-2020
Patient Information leaflet Patient Information leaflet Polish 27-10-2020
Public Assessment Report Public Assessment Report Polish 27-10-2020
Patient Information leaflet Patient Information leaflet Portuguese 27-10-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 27-10-2020
Public Assessment Report Public Assessment Report Portuguese 27-10-2020
Patient Information leaflet Patient Information leaflet Romanian 27-10-2020
Public Assessment Report Public Assessment Report Romanian 27-10-2020
Patient Information leaflet Patient Information leaflet Slovak 27-10-2020
Public Assessment Report Public Assessment Report Slovak 27-10-2020
Patient Information leaflet Patient Information leaflet Slovenian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 27-10-2020
Public Assessment Report Public Assessment Report Slovenian 27-10-2020
Patient Information leaflet Patient Information leaflet Finnish 27-10-2020
Public Assessment Report Public Assessment Report Finnish 27-10-2020
Patient Information leaflet Patient Information leaflet Swedish 27-10-2020
Public Assessment Report Public Assessment Report Swedish 27-10-2020
Patient Information leaflet Patient Information leaflet Norwegian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 27-10-2020
Patient Information leaflet Patient Information leaflet Icelandic 27-10-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 27-10-2020
Patient Information leaflet Patient Information leaflet Croatian 27-10-2020
Public Assessment Report Public Assessment Report Croatian 27-10-2020